Marc Dall'Era

Title(s)Professor, Urology
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Liquid biomarkers in active surveillance. World J Urol. 2022 Jan; 40(1):21-26. Dall'Era M. PMID: 33590279.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    2. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Med. 2019 10 17; 11(1):60. de Jong JJ, Liu Y, Robertson AG, Seiler R, Groeneveld CS, van der Heijden MS, Wright JL, Douglas J, Dall'Era M, Crabb SJ, van Rhijn BWG, van Kessel KEM, Davicioni E, Castro MAA, Lotan Y, Zwarthoff EC, Black PC, Boormans JL, Gibb EA. PMID: 31619281; PMCID: PMC6796434.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    3. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. PMID: 31128968.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    4. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 Jul; 12(7):871-878. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. PMID: 31075528; PMCID: PMC6510951.
      View in: PubMed   Mentions: 9  
    5. Editorial Comment. J Urol. 2019 05; 201(5):935-936. Dall'Era M. PMID: 30822206.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 07 01; 25(13):3908-3920. Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. PMID: 30952638.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    7. Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. BJU Int. 2019 11; 124(5):730-737. Glass AS, Dall'Era MA. PMID: 30740876.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    8. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018 11 16; 9(1):4700. Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. PMID: 30446660; PMCID: PMC6240084.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    9. Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer. BJU Int. 2018 11; 122(5):721-722. Chandrasekar T, Dall'Era MA, Tilki D. PMID: 30358932.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men. Am J Prev Med. 2018 11; 55(5 Suppl 1):S103-S111. Rogers CR, Rovito MJ, Hussein M, Obidike OJ, Pratt R, Alexander M, Berge JM, Dall'Era M, Nix JW, Warlick C. PMID: 30670195; PMCID: PMC6352989.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    11. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Cancer Res. 2019 08 15; 25(16):5082-5093. Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC. PMID: 30224344.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    12. New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose? Eur Urol. 2018 11; 74(5):549-550. Dall'Era MA, De Vere White RW. PMID: 30177292.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Editorial Comment. J Urol. 2018 11; 200(5):1003-1004. Stern M, Phillips JL. PMID: 30030970.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Reply to Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture? Cancer. 2018 09 01; 124(17):3619-3620. Dall'Era MA, Lo MJ, Chen JY, Cress R, Hamilton AS. PMID: 29975411; PMCID: PMC7583679.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. PMID: 29882105.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. Eur Urol Focus. 2019 11; 5(6):1014-1021. Dall'Era MA, deVere-White R, Rodriguez D, Cress R. PMID: 29735368.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    17. Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol. 2018 07; 36(7):342.e7-342.e14. Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM. PMID: 29657089.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    18. Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):236-242. Glass AS, Dall'Era MA. PMID: 29732282; PMCID: PMC5911543.
      View in: PubMed   Mentions:
    19. Active surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):195-196. Dall'Era MA, Davies BJ, Eggener S. PMID: 29732276; PMCID: PMC5911535.
      View in: PubMed   Mentions:
    20. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. Cancer. 2018 05 01; 124(9):1921-1928. Dall'Era MA, Lo MJ, Chen J, Cress R, Hamilton AS. PMID: 29499075; PMCID: PMC7492103.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. J Urol. 2018 06; 199(6):1452-1458. Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W, Collaborators. PMID: 29329894.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    22. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 04; 73(4):572-582. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. PMID: 29129398.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    23. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Sci Rep. 2017 09 25; 7(1):12277. Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. PMID: 28947782; PMCID: PMC5612935.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    24. A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome. Can Urol Assoc J. 2017 Sep; 11(9):E344-E349. Yuh LM, Lara PN, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA. PMID: 29382456; PMCID: PMC5798438.
      View in: PubMed   Mentions: 2  
    25. Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer. Clin Genitourin Cancer. 2017 Jul 14. Glass AS, Pugashetti NB, Dall'Era MA, Evans CP, Yap SA. PMID: 28789835.
      View in: PubMed   Mentions:    Fields:    
    26. Editorial Comment. J Urol. 2017 08; 198(2):328. Dall'Era M. PMID: 28506736.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. PMID: 28390739.
      View in: PubMed   Mentions: 316     Fields:    Translation:HumansCells
    28. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 03; 20(1):1-6. Dall'Era MA, Klotz L. PMID: 27801900; PMCID: PMC5303136.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    29. Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. J Urol. 2017 01; 197(1):8-9. Dall'Era M, Evans C. PMID: 27746279.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. PMID: 27640312; PMCID: PMC6522262.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    31. Perioperative Outcomes following Neoadjuvant Chemotherapy and Radical Cystectomy—Is There Room for Improvement?. Urology Practice. 2016 Sep 1; 3(5):364-370. Pugashetti PN, Chandrasekar CT, Lurvey LR, Durbin-Johnson DB, Dall'Era DM, White WR, Evans EC, Yap YS. .
      View in: Publisher Site   Mentions:
    32. Reasons for Abandonment of Active Surveillance in Men with Prostate Cancer. J Urol. 2016 09; 196(3):637-8. Dall'Era MA. PMID: 27316451.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb; 35(2):277-283. Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN. PMID: 27306686.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. PMID: 27019001; PMCID: PMC4892938.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    35. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? J Urol. 2016 Apr; 195(4 Pt 1):886-93. Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P, Collaborators. PMID: 26521718.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    36. DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 2015 Sep; 16(9):1219-32. Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R. PMID: 26206718; PMCID: PMC4576988.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    37. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer? J Urol. 2015 Sep; 194(3):615-6. Dall'Era M, Carroll P. PMID: 26079332.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Patient and disease factors affecting the choice and adherence to active surveillance. Curr Opin Urol. 2015 May; 25(3):272-6. Dall'Era MA. PMID: 25692724.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    39. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015 Aug; 194(2):304-308. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. PMID: 25797392; PMCID: PMC5012645.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    40. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Can Urol Assoc J. 2015 Mar-Apr; 9(3-4):E204-7. Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall'Era MA. PMID: 26085880; PMCID: PMC4455640.
      View in: PubMed   Mentions: 5  
    41. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (Lond). 2015; 10(7):1189-201. Tomlinson B, Lin TY, Dall'Era M, Pan CX. PMID: 25929573; PMCID: PMC4562431.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    42. Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review. J Urol. 2015 May; 193(5):1525-31. Tilki D, Kim SI, Hu B, Dall'Era MA, Evans CP. PMID: 25444980.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    43. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. PMID: 25257030; PMCID: PMC4840190.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    44. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015 Feb; 193(2):436-42. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. PMID: 25063493.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    45. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014 Mar 15; 120(6):818-23. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. PMID: 24258693.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    46. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol. 2014 Sep; 66(3):577-83. Tilki D, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. PMID: 23871402.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    47. The economics of active surveillance for prostate cancer. Curr Opin Urol. 2013 May; 23(3):278-82. Dall'Era MA. PMID: 23449496.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    48. Editorial comment. J Urol. 2013 Jul; 190(1):96. Dall'Era M. PMID: 23624151.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Editorial Comment. The Journal of Urology. 2013 Jan 1; 189(1):s25. Dall'Era DM. .
      View in: Publisher Site   Mentions:
    50. Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2012 Jul; 12(7):941-50. Dall'Era MA, Cheng L, Pan CX. PMID: 22845409; PMCID: PMC3494992.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    51. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. PMID: 22698574.
      View in: PubMed   Mentions: 208     Fields:    Translation:Humans
    52. Economic analysis of active surveillance for localized prostate cancer. Curr Opin Urol. 2012 May; 22(3):247-53. Kim S, Dall'Era MA, Evans CP. PMID: 22388666.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    53. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012 Jul 15; 118(14):3512-8. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. PMID: 22180322; PMCID: PMC3698480.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    54. Pretreatment imaging can be used to select imaging guidance, ultrasound alone versus CT plus ultrasound, for percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2011 Nov; 197(5):1244-50. McGahan JP, Loh S, Fitzgerald E, Koppie T, Evans CP, Dall'Era M, Li CS. PMID: 22021521.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. PMID: 20804478.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    56. Active surveillance for localized prostate cancer--current practices and recommendations. ScientificWorldJournal. 2010 Dec 14; 10:2352-61. Wu JN, Dall'Era MA. PMID: 21170486; PMCID: PMC5763778.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    57. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol. 2009 Jul; 182(1):112-7; discussion 117. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll PR. PMID: 19447437.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    58. Outcomes and follow-up strategies for patients on active surveillance. Curr Opin Urol. 2009 May; 19(3):258-62. Dall'Era MA, Carroll PR. PMID: 19295434.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    59. Editorial Comment. The Journal of Urology. 2009 Apr 1; 181(4):1641. Dall'Era DM. .
      View in: Publisher Site   Mentions:
    60. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol. 2009 Apr; 181(4):1622-7; discussion 1627. Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. PMID: 19230923.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    61. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009 Apr; 181(4):1628-33; discussion 1633-4. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. PMID: 19233388.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansPHPublic Health
    62. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. PMID: 18433013.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    63. Pelvic lymphadenectomy in prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(4):320-4. Breyer BN, Greene KL, Dall'Era MA, Davies BJ, Kane CJ. PMID: 18490935.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    64. Watchful waiting versus active surveillance: appropriate patient selection. Curr Urol Rep. 2008 May; 9(3):211-6. Dall'Era MA, Kane CJ. PMID: 18765115.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    65. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll PR. PMID: 18306379.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansPHPublic Health
    66. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nat Clin Pract Urol. 2008 May; 5(5):277-83. Dall'Era MA, Konety BR. PMID: 18285752.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    67. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol. 2007 Oct; 178(4 Pt 1):1440-6; discussion 1446. Walsh TJ, Dall'Era MA, Croughan MS, Carroll PR, Turek PJ. PMID: 17706709.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    68. The optimal management of clinically localized prostate cancer: the debate continues. Nat Clin Pract Urol. 2007 Sep; 4(9):474-5. Dall'Era M, Konety B. PMID: 17653197.
      View in: PubMed   Mentions: 1     Fields:    
    69. HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells. Prostate. 2007 May 15; 67(7):714-21. Dall'Era MA, Oudes A, Martin DB, Liu AY. PMID: 17342744.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    70. Prostate cancer--more information and more questions. J Urol. 2007 May; 177(5):1607-8. Dall'Era M, Carroll PR. PMID: 17437768.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    71. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Mar 02; 7:3. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. PMID: 17335564; PMCID: PMC1829163.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    72. Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol. 2006 Jul; 176(1):87-90. Dall'Era MA, Hampson NB, Hsi RA, Madsen B, Corman JM. PMID: 16753375.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    73. Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Prostate Cancer Prostatic Dis. 2003; 6(2):131-7. Shih SJ, Dall'Era MA, Westphal JR, Yang J, Sweep CG, Gandour-Edwards R, Evans CP. PMID: 12806371.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    74. Regulation of u-PA gene expression in human prostate cancer. Int J Cancer. 2001 Nov 01; 94(3):390-5. Evans CP, Stapp EC, Dall'Era MA, Juarez J, Yang JC. PMID: 11745419.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    75. Benign medullary fibroma of the kidney. J Urol. 2000 Dec; 164(6):2018. Dall'Era M, Das S. PMID: 11061906.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995 Mar; 153(3 Pt 2):993-9. Wolf JS, Cher M, Dall'era M, Presti JC, Hricak H, Carroll PR. PMID: 7853590.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials